Profile data is unavailable for this security.
About the company
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
- Revenue in HKD (TTM)21.57bn
- Net income in HKD-6.12bn
- Incorporated2010
- Employees10.60k
- LocationBeigene Ltd94 Solaris Avenue,, Camana BayGRAND CAYMAN KY1-1108Cayman IslandsCYM
- Phone+1 3 459494123
- Websitehttps://www.beigene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.66bn | -619.08m | 40.33bn | 1.42k | -- | 15.21 | -- | 23.38 | -2.79 | -2.79 | 7.58 | 11.46 | -- | -- | -- | 1,173,923.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Akeso Inc | 4.88bn | 2.19bn | 40.96bn | 2.78k | 18.40 | 7.99 | 18.50 | 8.52 | 2.61 | 2.61 | 5.83 | 6.02 | 0.6168 | 0.3749 | 15.98 | 1,756,883.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Sino Biopharmaceutical Ltd | 28.25bn | 1.99bn | 55.28bn | 25.81k | 27.27 | 1.64 | 9.09 | 1.95 | 0.1074 | 0.1357 | 1.52 | 1.79 | 0.4104 | 2.31 | 5.73 | 1,094,730.00 | 7.23 | 13.11 | 13.37 | 21.74 | 80.95 | 80.37 | 17.61 | 27.47 | 0.9649 | 11.83 | 0.2479 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| WuXi Biologics (Cayman) Inc | 18.37bn | 3.67bn | 56.07bn | 12.74k | 15.28 | 1.26 | 10.27 | 2.99 | 0.8429 | 0.8429 | 4.22 | 10.26 | 0.321 | 5.04 | 3.02 | 1,441,750.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Innovent Biologics Inc | 6.69bn | -1.11bn | 61.83bn | 4.87k | -- | 4.44 | -- | 9.00 | -0.7028 | -0.7028 | 4.29 | 8.33 | 0.3248 | 0.9481 | 7.85 | 1,373,553.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -162.51 | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| CSPC Pharmaceutical Group Ltd | 33.91bn | 6.33bn | 77.44bn | 23.50k | 12.07 | 2.14 | 9.89 | 2.26 | 0.5334 | 0.5334 | 2.86 | 3.01 | 0.7144 | 3.26 | 6.21 | 1,443,080.00 | 13.79 | 16.08 | 18.50 | 21.57 | 70.51 | 72.95 | 19.31 | 19.63 | 2.32 | -- | 0.0198 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Hansoh Pharmaceutical Group Company Ltd | 10.89bn | 3.53bn | 102.09bn | 9.12k | 29.51 | 3.68 | 26.10 | 9.41 | 0.5856 | 0.5856 | 1.81 | 4.70 | 0.3206 | 2.02 | 3.00 | 1,194,218.00 | 10.40 | 11.58 | 12.24 | 13.98 | 89.78 | 90.78 | 32.44 | 29.28 | 4.12 | -- | 0.143 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
| Beigene Ltd | 21.57bn | -6.12bn | 143.77bn | 10.60k | -- | -- | -- | 6.37 | -4.55 | -4.55 | 15.80 | -- | -- | -- | -- | -- | -- | -26.72 | -- | -33.85 | 74.76 | 83.19 | -28.39 | -120.76 | -- | -- | -- | -- | 73.65 | 65.47 | 56.00 | -- | 33.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (International Investors)as of 29 Dec 2023 | 103.42m | 8.32% |
| HHLR Advisors Ltd.as of 19 Apr 2024 | 75.59m | 6.08% |
| The Vanguard Group, Inc.as of 09 May 2024 | 24.69m | 1.99% |
| BlackRock Fund Advisorsas of 09 May 2024 | 15.07m | 1.21% |
| Capital International, Inc.as of 26 Jan 2024 | 11.06m | 0.89% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 10.31m | 0.83% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 6.11m | 0.49% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 3.62m | 0.29% |
| Geode Capital Management LLCas of 16 May 2024 | 3.20m | 0.26% |
| Candriam Belgium SAas of 29 Mar 2024 | 3.09m | 0.25% |
